🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
13/10/2022 1,4100 USD
14/07/2022 1,4100 USD
13/04/2022 1,4100 USD
13/01/2022 1,4100 USD
14/10/2021 1,3000 USD
14/07/2021 1,3000 USD
14/04/2021 1,3000 USD
14/01/2021 1,3000 USD
14/10/2020 1,1800 USD
14/07/2020 1,1800 USD
14/04/2020 1,1800 USD
14/01/2020 1,1800 USD
11/10/2019 1,0700 USD
12/07/2019 1,0700 USD
12/04/2019 1,0700 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
07/07/2014 57,91 58,15 57,39 57,40 -1,41% 1,31% 4.736.300
03/07/2014 57,90 58,27 57,65 58,22 +0,19% 1,07% 3.828.900
02/07/2014 57,46 58,11 56,92 58,11 +2,14% 2,07% 6.198.500
01/07/2014 56,42 57,20 56,17 56,89 +0,80% 1,83% 6.869.800
30/06/2014 56,51 56,89 56,10 56,44 -0,62% 1,40% 6.229.700
27/06/2014 56,58 56,90 56,28 56,79 +0,50% 1,10% 7.490.800
26/06/2014 55,07 56,54 54,97 56,51 +2,75% 2,85% 10.716.400
25/06/2014 53,52 55,79 53,40 55,00 +2,63% 4,47% 11.085.100
24/06/2014 53,74 53,95 53,43 53,59 -0,30% 0,97% 5.483.500
23/06/2014 53,76 54,40 53,54 53,75 +0,84% 1,60% 6.235.600
20/06/2014 55,62 55,62 53,16 53,30 -1,64% 4,42% 13.457.700
19/06/2014 54,14 54,81 53,92 54,19 -0,70% 1,64% 3.952.800
18/06/2014 54,27 54,61 54,00 54,57 +0,50% 1,12% 3.337.300
17/06/2014 54,49 54,54 53,85 54,30 +0,56% 1,27% 3.385.000
16/06/2014 54,18 54,31 53,45 54,00 -0,30% 1,59% 4.410.400
13/06/2014 53,67 54,31 53,44 54,16 +0,93% 1,62% 4.413.000
12/06/2014 54,22 54,25 53,46 53,66 -1,05% 1,46% 3.941.600
11/06/2014 53,85 54,70 53,75 54,23 +0,48% 1,76% 5.386.800
10/06/2014 53,14 54,08 52,29 53,97 +0,24% 3,37% 8.414.700
09/06/2014 54,42 54,88 53,72 53,84 -2,29% 2,13% 6.297.500
06/06/2014 55,32 55,40 54,89 55,10 -0,36% 0,92% 3.449.800
05/06/2014 54,55 55,32 54,36 55,30 +1,32% 1,76% 4.847.300
04/06/2014 53,92 54,64 53,67 54,58 +0,39% 1,80% 3.388.200
03/06/2014 54,06 54,47 53,87 54,37 +0,41% 1,11% 3.078.000
02/06/2014 54,43 54,95 53,91 54,15 -0,33% 1,91% 3.635.000
30/05/2014 53,98 54,43 53,89 54,33 +0,56% 1,00% 4.025.600
29/05/2014 54,10 54,45 53,75 54,03 -0,07% 1,29% 2.768.600
28/05/2014 53,96 54,61 53,82 54,07 +0,15% 1,46% 4.108.300
27/05/2014 54,20 54,20 53,78 53,99 +0,07% 0,77% 3.816.300
23/05/2014 53,94 54,38 53,84 53,95 +0,60% 1,00% 3.023.500